AEGiS-Reuters: South Africa Approves Mass HIV/AIDS Drug Treatment

Reuters, Ltd.Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
Click here to return to Reuters main menu






DonateNow


South Africa Approves Mass HIV/AIDS Drug Treatment

Reuters NewMedia - Wednesday November 19, 2003
Gordon Bell


CAPE TOWN (Reuters) - South Africa approved a national drug treatment program on Wednesday to tackle the world's highest AIDS caseload, bowing to pressure to act against an epidemic killing an estimated 600 South Africans each day.

Health Minister Manto Tshabalala-Msimang told reporters that within a year there would be a network of centers to distribute anti-retroviral (ARV) drugs, which the government previously resisted providing to the public sector.

"Cabinet today in principle approved the operational plan for comprehensive treatment and care for HIV and AIDS," Tshabalala-Msimang said after a cabinet meeting.

Nearly five million of South Africa's 45 million people have AIDS or HIV, the virus which causes it, giving it the world's highest caseload.

Activists say 600 South Africans die of AIDS each day, and that many of them could be saved by ARVs.

President Thabo Mbeki's cabinet has long resisted calls for free drug treatment to those infected, but under huge domestic and international pressure ordered the Department of Health in August to draw up a national treatment plan.

Last week Finance Minister Trevor Manuel said South Africa would spend $1.75 billion over the next three years on HIV/AIDS, with 1.9 billion rand earmarked for the roll-out of anti-retroviral drugs.

Tshabalala-Msimang said that within a year there would be at least one center distributing anti-retroviral drugs in each of South Africa's 50 or so health districts, rising to at least one in every one of over 250 local municipalities by 2009.

She added the government estimated more than 50,000 people could be getting the drugs in the first year of the program.

LOTS OF WORK AHEAD

She stressed that ARVS were only one prong of South Africa's AIDS strategy, saying more than half the government's AIDS budget would go to "upgrading health infrastructure, emphasizing prevention, and promoting healthy lifestyles."

The question of treatment had threatened to dominate the run-up to next year's general elections marking 10 years since the end of apartheid rule.

Mbeki himself long backed so-called "AIDS dissident" scientists who questioned the link between AIDS and HIV. He has since withdrawn from the public discussion over the disease.

Tshabalala-Msimang -- dubbed "Dr No" by the local media for previously rejecting calls for public ARV treatment -- said the government had finally approved a drug plan because of falling drug prices, increased experience in managing ARV treatment programs and expanded financial resources.

"So it has nothing to do with elections, it has absolutely everything to do with the capacity that we have," she said.

Mbeki's ruling African National Congress gave a grudging welcome to the plan.

"For too long, opportunists have used the AIDS epidemic and the suffering of our people as a political football. The government has correctly remained above the fray, consistently working instead to develop responses which are feasible and sustainable," the ANC said in a statement.

Activists were overjoyed by Tshabalala-Msimang's announcement, saying it marked a victory after years of pushing the government for action.

"I'm so excited regarding the plans produced today," Ntombozuko Khwaza, a provincial coordinator for the Treatment Action Campaign, a pressure group which has led public protests demanding ARV treatment.

"It will save the lives of our people, our friends and family -- and mine."


031119
RE031116


Copyright © 2003 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.   Contact Reuters.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .